Clinical Trial Update: To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

View source ↗

Summary

Clinical trial results describe how axitinib dose reductions and temporary interruptions were used to manage adverse events in patients with advanced renal cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Pfizer | Conditions: Renal Cell Carcinoma | Status: COMPLETED | Results posted: 2025-01-03